On January 12, 2026, Assertio Holdings, Inc. confirmed that it has satisfied Nasdaq’s Minimum Bid Price Rule by maintaining a closing bid above $1.00 per share for ten consecutive trading days, thereby restoring full compliance with all applicable listing standards. The company achieved this milestone following its December 2025 reverse stock-split, which consolidated its share structure and bolstered its per-share price without issuing new equity. CEO Mark Reisenauer highlighted that the transaction was completed efficiently and preserved Assertio’s flexibility to allocate capital toward growth initiatives in oncology, neurology, and pain management. Nasdaq’s notice formally closes the previous deficiency matter, ensuring uninterrupted trading eligibility and reaffirming the company’s commitment to market standards.